Skip to content

Skeletal Muscle Wasting in ICU Patients

Skeletal Muscle Wasting in ICU Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06234826
Acronym
IC-MPS
Enrollment
20
Registered
2024-01-31
Start date
2023-04-17
Completion date
2025-04-30
Last updated
2024-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Muscle Atrophy

Brief summary

Muscle wasting occurs rapidly in critically ill patients and impacts both short and long term outcomes. Altered protein metabolism drives muscle loss in ICU patients, with muscle protein breakdown exceeding muscle protein synthesis (MPS). Interventions aimed at attenuating muscle loss by stimulating MPS rates are hampered by a lack of knowledge on altered muscle protein turnover rates during critical illness. Only a few studies have specifically assessed muscle protein synthesis by using contemporary intravenous stable isotope infusions, which allows the assessment of MPS over a short (\<9 hours) period of time. Results from such acute studies can be difficult to extend or translate into long-term clinical practice and outcomes. Oral deuterated water (2H2O) dosing provides an alternative method that can be utilized to extend the measurement of muscle protein synthesis over a period of several days or weeks. It could therefore provide a valuable tool to study muscle protein synthesis during ICU admission and the impact of different anabolic interventions. Although multiple studies using the deuterated water methodology have been performed in both healthy volunteers and patients, it has not yet been performed in critically ill patients. In this prospective study the investigators aim to assess fractional rates of muscle protein synthesis over a period of (maximal) 7 days in critically ill patients admitted to the intensive care unit. Secondly, the investigators aim to assess mechanisms of acute muscle wasting on an microscopic, ultrastructural and molecular level. Furthermore, the investigators aim to investigate to what extent muscle fibre size is recovered 3 months after ICU discharge.

Interventions

None listed

Sponsors

Jessa Hospital
CollaboratorOTHER
Frank Vandenabeele
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* age \>18y * admitted to ICU * enteral nutrition line in situ * arterial line (any location) in situ * expected stay ICU \>7d

Exclusion criteria

* spinal cord injury * chronic use of corticosteroids before hospital admission * Contraindication to enteral infusion (e.g. due to GI-tract perforation) * Kidney or liver failure * therapeutic anti coagulation

Design outcomes

Primary

MeasureTime frameDescription
muscle protein synthesis rate (%/h)7 days of stay at the intensive care unitobtained by using deuterated water, muscle biopsy sampling and blood sampling

Secondary

MeasureTime frameDescription
skeletal muscle fiber characteristics 27 days of stay at the intensive care unitamount and distribution of muscle fibers (distribution will be calculated as: amount of type X / total amount of fibres)
mRNA expression in skeletal muscle tissue 17 days of stay at the intensive care unitmRNA expression in skeletal muscle tissue of MAFBx (atrophy marker)
mRNA expression in skeletal muscle tissue 27 days of stay at the intensive care unitmRNA expression in skeletal muscle tissue of MurF1 (atrophy marker)
mRNA expression in skeletal muscle tissue 37 days of stay at the intensive care unitmRNA expression in skeletal muscle tissue of FOXO (atrophy marker)
patient characteristic- age7 days of stay at the intensive care unitage in years
patient characteristic- body weight7 days of stay at the intensive care unitbody weight in kg
patient characteristic- height7 days of stay at the intensive care unitheight in m
patient characteristic- sex7 days of stay at the intensive care unitmale or female
patient characteristics (medical1)7 days of stay at the intensive care unitmechanical ventilation (duration in days)
patient characteristics (medical2)7 days of stay at the intensive care unitcomorbidities (list of comorbidities)
patient characteristics (medical3)7 days of stay at the intensive care unitreason hospital admission
skeletal muscle fiber characteristics 17 days of stay at the intensive care unitcross sectional area of muscle fibers
patient characteristic- food intake7 days of stay at the intensive care unitfood intake (energy in kcal and protein intake in g/kg/d)
patient characteristic- LOSStay at the intensive care unit and Hospital (up to 1 year)Length of stay ICU and hospital (in days)
muscle hand grip strength3 months post-hospital dischargehand grip strength using the JAMAR dynamometer in kg
leg muscle strength3 months post-hospital discharge1RM upper leg at follow up visit
muscle volume3 months post-hospital discharge3d ultrasound assessed at follow up visit
habitual food3 months post-hospital dischargeAssessed using questionnaires at follow up visit (higher score means better intake)
habitual activity3 months post-hospital dischargeAssessed using questionnaires at follow up visit (higher score means better intake)
Functional capacity 13 months post-hospital dischargeSPPB at follow up visit (short physical performance battery)
Functional capacity 23 months post-hospital discharge6min walking test at follow up visit
Quality of life questionnaire3 months post-hospital dischargeSF-36 at follow up visit (Short Form Health Survey 36 items) range score between 0-100, lower score represents great health related problems
Quality of life questionnaires3 months post-hospital dischargeEuro-QoL-5D-5-level at follow up visit (Euro quality of life 5 Dimension 5 level) Answers can be converted into EQ-5D index, an utility scores anchored at 0 for death and 1 for perfect health
patient characteristic- APACHE score II7 days of stay at the intensive care unitAPACHE II score = acute physiology score + age points + chronic health points. Minimum score = 0; maximum score = 71.

Countries

Belgium

Contacts

Primary ContactMichelle Weijzen, Dr.
michelle.weijzen@uhasselt.be003211268706
Backup ContactFrank Vandenabeele, Prof.
frank.vandenabeele@uhasselt.be

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026